Chapter 1. Global Erythropoietin Stimulating Agents Market – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Global Erythropoietin Stimulating Agents Market – Executive Summary
2.1. Market Size & Forecast – (2022 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 & Russia Ukraine War Impact Analysis
2.3.1. Impact during 2023 - 2030
2.3.2. Impact on Supply – Demand
Chapter 3. Global Erythropoietin Stimulating Agents Market – Competition Scenario
3.1. Market Share Analysis
3.2. Company Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier Distributor Analysis
Chapter 4. Global Erythropoietin Stimulating Agents Market Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Global Erythropoietin Stimulating Agents Market - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Global Erythropoietin Stimulating Agents Market – By Type
6.1. Epoetin alfa
6.2. Epoetin beta
6.3. Darbepoetin alfa
6.4. Other ESAs
Chapter 7. Global Erythropoietin Stimulating Agents Market – By Application
7.1. Anemia of chronic kidney disease (CKD)
7.2. Chemotherapy-induced anemia (CIA)
7.3. Pure red cell aplasia (PRCA)
7.4. Other applications
Chapter 8. Global Erythropoietin Stimulating Agents Market, By Geography - Market Size, Forecast, Trends & Insights
8.1. North America
8.1.1. U.S.A
8.1.2. Canada
8.1.3. Mexico
8.2. Europe
8.2.1. U.K.
8.2.2. Germany
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest Of Europe
8.3. Asia Pacific
8.3.1. Japan
8.3.2. South Korea
8.3.3. China
8.3.4. India
8.3.5. Australia & New Zealand
8.3.6. Rest of Asia-Pacific
8.4. South America
8.4.1. Brazil
8.4.2. Argentina
8.4.3. Colombia
8.4.4. Chile
8.4.5. Rest of South America
8.5. Middle East & Africa
8.5.1. United Arab Emirates (UAE)
8.5.2. Saudi Arabia
8.5.3. Qatar
8.5.4. Israel
8.5.5. South Africa
8.5.6. Nigeria
8.5.7. Kenya
8.5.8. Egypt
8.5.9. Rest of MEA
Chapter 9. Global Erythropoietin Stimulating Agents Market– Company Profiles – (Overview, Product Portfolio, Financials, Developments)
9.1. Amgen
9.2. Johnson & Johnson
9.3. Pfizer
9.4. Roche
9.5. Chugai Pharmaceutical
9.6. Teva Pharmaceutical
9.7. Celltrion
9.8. Evox Therapeutics
9.9. Biocon
9.10. Novartis
9.11. Sandoz
9.12. Fresenius Kabi
9.13. Hanmi Pharmaceutical
2850
5250
4500
1800
Frequently Asked Questions
The Global Erythropoietin Stimulating Agents (ESA) Market was valued at USD 15.2 Billion and is projected to reach a market size of USD 27.5 Billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 8.84%.
The Global Erythropoietin Stimulating Agents (ESA) Market finds application primarily in treating anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and conditions such as HIV-associated anemia, reflecting its vital role in addressing diverse hematologic challenges.
Disruptions in supply chains, a reduction in elective surgeries, and concerns about ESA-related immunosuppression posed challenges. Conversely, heightened awareness of anemia among COVID-19 patients has increased ESA demand, and the crisis accelerated research, fostering innovation in ESA development.
Key market players include Amgen, Johnson & Johnson, Pfizer, Roche, Chugai Pharmaceutical, Teva Pharmaceutical, Celltrion, Evox Therapeutics, Biocon, Novartis, Sandoz, Fresenius Kabi, Hanmi Pharmaceutical.
The primary drivers fueling the growth of the Global Erythropoietin Stimulating Agents (ESA) Market include the increasing prevalence of anemia, particularly in aging populations and patients with chronic diseases, the rising adoption of ESAs across various medical conditions, and ongoing research and development efforts to expand applications and develop novel, more effective ESAs.